Press Releases Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
15.43 ^USD	+3.14%		-3.56%	-28.10%

Apr. 09	UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	MT
Apr. 03	Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	Apr. 09	AQ
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	Feb. 27	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	Feb. 27	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	Feb. 27	AQ
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	Feb. 07	GL
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	Feb. 07	AQ
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	Feb. 01	GL
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	Feb. 01	AQ
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	Jan. 08	GL
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	Jan. 08	AQ
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights	Nov. 07	GL
MOMENTUM IN ALZHEIMER'S RESEARCH GUIDED BY THE BIOLOGY OF AGING TO BE HIGHLIGHTED IN SESSION MODERATED BY ALZHEIMER'S DRUG DISCOVERY FOUNDATION AT 2023 CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE	23-10-18	AQ
Metachromatic Leukodystrophy Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-09	AQ
ProFound Therapeutics Expands Leadership Team with Appointment of Klaus Urbahns as Chief Scientific Officer	23-09-26	AQ
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023	23-08-30	GL
ALLTRNA EXPANDS LEADERSHIP TEAM WITH APPOINTMENTS OF CHIEF SCIENTIFIC OFFICER AND CHIEF TECHNOLOGY OFFICER	23-08-16	AQ
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines	23-08-15	AQ
ALLTRNA ANNOUNCES SERIES B RAISE OF $109 MILLION TO ADVANCE TRNA MEDICINES FOR STOP CODON DISEASE	23-08-10	AQ
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights	23-08-08	GL
Senda Biosciences Appoints Igor Matushansky as Chief Medical Officer	23-07-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Press Releases

Filters